Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO₂ Requirements.

For the secondary endpoint of time to viral clearance, despite randomization being a median of 11 days after symptom onset for both opaganib and placebo cohorts, opaganib demonstrated a nominally significant improvement as compared to placebo, with a hazard ratio of 1.34 and a nominal p -value of 0.043 as shown in Figure 2 (and Table 3 ).

also in 7,732 other papers